Should I Buy GMAB? GMAB 2026 Analysis

Should You Buy Genmab A/S (GMAB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

30.900

1 Day change

-0.23%

52 Week Range

35.430

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Intellectia Proprietary Trading Signals\n- AI Stock Picker: No signal on given stock today.\n- SwingMax: No signal on given stock recently.\n- Buy now, but size it as a “support-entry”: price is sitting right on key support (S1 ~31.85) after a sharp -3.54% regular-session drop; risk/reward favors an entry at support rather than chasing strength.\n- Wall St. is broadly constructive (mostly Buy/Overweight with targets materially above spot), and 2026 is framed as catalyst-heavy by multiple firms.\n- Options flow is more bullish than bearish today (call-heavy volume) despite put-heavy open interest (hedging), which fits a dip-buying setup near support.

Technical Analysis

Trend/Momentum: Bearish short-term momentum. MACD histogram -0.184 and negatively expanding suggests downside pressure is still active.\n- RSI (6): 35.97, approaching oversold; often consistent with “selloff near exhaustion” conditions, especially when price is at support.\n- Moving averages: Converging MAs indicate consolidation/transition; not a clean uptrend yet, but often precedes a larger move once support holds.\n- Key levels: Pivot 33.10 is overhead (now resistance). Immediate support S1 31.85 (price ~31.9–32.05 post), next support S2 31.08. Resistance levels: R1 34.34, R2 35.12.\n- Pattern-based forward bias (provided): modestly positive skew over 1 week (+2.49% expected), near-flat 1 month (+0.32%), implying the bigger edge is in a near-term bounce rather than a sustained trend.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

\n- Positioning (Open Interest): Put/Call OI ratio 1.2 = more puts outstanding than calls (more hedging/defensive positioning).\n- Today’s activity (Volume): Put/Call volume ratio 0.17 with calls 36 vs puts 6 = today’s flow is call-dominant (tends to be short-term bullish).\n- Volatility: 30D IV 62.45 vs historical vol 43.06 (IV elevated), consistent with heightened catalyst/uncertainty pricing.\n- Unusual activity: Today’s volume vs 30D avg 11.57 and open interest metrics elevated (todays OI 8265; today vs OI avg 128.38) suggests increased attention and positioning into/around an event window.

Technical Summary

Sell

Buy

Positive Catalysts

- Analyst framing of 2026 as “catalyst rich” with multiple major catalysts (per BofA), each viewed as potentially large commercial opportunities.\n- Truist remains optimistic on the key frontline DLBCL readout despite the trial miss in a different setting, suggesting a still-live upside catalyst.\n- Strong recent operating performance (2025/Q3): revenue +25% YoY and EPS +121% YoY supports confidence in the core business trajectory.

Neutral/Negative Catalysts

as the next magnet level.\n- News feed provided appears not directly about Genmab (Oncolytics Biotech items), reducing confidence that there’s a near-term positive news impulse specific to GMAB in the dataset.

Financial Performance

Latest quarter (2025/Q3): Revenue $1.022B, +25.25% YoY (solid top-line growth).\n- Profitability acceleration: Net income $401M, +115.59% YoY; EPS 6.46, +121.23% YoY (strong operating leverage).\n- Margins: Gross margin 94.32% (down -0.82% YoY) — still extremely high, slight compression but not thesis-breaking based on this snapshot.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent direction: Predominantly bullish (Buy/Overweight maintained), with some price target raises (BofA to $38.50; DB/Barclays raised local-currency targets) and one cut (H.C. Wainwright to $39 from $41) after the endpoint miss.\n- Price target range (USD-listed notes): ~$38.50 to $48 vs current ~$32 area, implying meaningful upside if catalysts land well.\n- Wall Street pros: Catalyst-heavy 2026 setup; confidence that the key frontline DLBCL program remains intact; core business strength reflected in recent quarter growth.\n- Wall Street cons: Recent trial miss increases clinical uncertainty and can sustain a discount until clearer efficacy signals emerge.

7 Analyst Rating

Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 38.5 USD with a low forecast of 26 USD and a high forecast of 48 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

2 Hold

0 Sell

Moderate Buy

Current: 30.970

Low

Averages

38.5

High

Current: 30.970

Low

Averages

38.5

High

H.C. Wainwright

Buy

downgrade

$41 -> $39

AI Analysis

2026-01-20

Reason

H.C. Wainwright

Price Target

$41 -> $39

AI Analysis

2026-01-20

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Genmab to $39 from $41 and keeps a Buy rating on the shares. The firm says that while EPCORE DLBCL-1 failed its primary endpoint, Epkinly may still gain full approval.

BofA

Buy

maintain

2026-01-19

Reason

BofA

Price Target

2026-01-19

maintain

Buy

Reason

BofA raised the firm's price target on Genmab to $38.50 from $34.70 and keeps a Buy rating on the shares. The company last week outlined a "catalyst rich" fiscal 2026, the analyst tells investors in a research note. The firm is "bullish" into Genmab's three major catalysts in 2026, seeing each offering a $2B peak sales opportunity in attractive markets.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GMAB

Unlock Now

GMAB Should I Buy

GMAB Should I Buy

Should You Buy Genmab A/S (GMAB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch